BACKGROUND: Spinal neurofibromas (SNFs) in neurofibromatosis type 1 (NF1) can cause progressive spinal cord compression and neurological dysfunction. The MEK inhibitor selumetinib shrinks the majority of plexiform neurofibromas (PNs) in patients with NF1. We assessed the effect of selumetinib on SNF. METHODS: Pediatric and adult patients with NF1 and inoperable PN participating in phase 2 studies of selumetinib for PN were included in this analysis if they had SNF and serial spine magnetic resonance imaging (MRI). Selumetinib was administered orally at the recommended dose of 25 mg/m2/dose twice daily (max 50 mg b.i.d.; 1 cycle = 28 days). We qualitatively assessed the effect of selumetinib on SNF-related spinal canal distortion, cerebrospinal fluid distribution, and spinal cord deformity on MRI. RESULTS: Twenty-four patients (18 male), median age 16.9 years (range, 6.2-60.3), had SNF, 22 of which were associated with the same nerves as the target PN assessed on the clinical trial. Twenty patients had spinal cord deformity. Twenty-three patients completed at least 12 treatment cycles to date. Eighteen patients showed subtle to a marked improvement in SNF burden, 5 remained stable, and no worsening was observed during treatment. CONCLUSIONS: This is the first study describing the effect of selumetinib on SNF. Of 24 patients, 18 exhibited some improvement of SNF burden on imaging. These findings suggest that selumetinib may prevent the worsening of cord compression, potentially reducing the need for surgical interventions in select patients or benefitting patients who do not have a surgical option. Prospective evaluation of the clinical benefit of selumetinib for SNF is warranted. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology 2020.
BACKGROUND: Spinal neurofibromas (SNFs) in neurofibromatosis type 1 (NF1) can cause progressive spinal cord compression and neurological dysfunction. The MEK inhibitor selumetinib shrinks the majority of plexiform neurofibromas (PNs) in patients with NF1. We assessed the effect of selumetinib on SNF. METHODS: Pediatric and adult patients with NF1 and inoperable PN participating in phase 2 studies of selumetinib for PN were included in this analysis if they had SNF and serial spine magnetic resonance imaging (MRI). Selumetinib was administered orally at the recommended dose of 25 mg/m2/dose twice daily (max 50 mg b.i.d.; 1 cycle = 28 days). We qualitatively assessed the effect of selumetinib on SNF-related spinal canal distortion, cerebrospinal fluid distribution, and spinal cord deformity on MRI. RESULTS: Twenty-four patients (18 male), median age 16.9 years (range, 6.2-60.3), had SNF, 22 of which were associated with the same nerves as the target PN assessed on the clinical trial. Twenty patients had spinal cord deformity. Twenty-three patients completed at least 12 treatment cycles to date. Eighteen patients showed subtle to a marked improvement in SNF burden, 5 remained stable, and no worsening was observed during treatment. CONCLUSIONS: This is the first study describing the effect of selumetinib on SNF. Of 24 patients, 18 exhibited some improvement of SNF burden on imaging. These findings suggest that selumetinib may prevent the worsening of cord compression, potentially reducing the need for surgical interventions in select patients or benefitting patients who do not have a surgical option. Prospective evaluation of the clinical benefit of selumetinib for SNF is warranted. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology 2020.
Authors: M Mauda-Havakuk; B Shofty; S Ben-Shachar; L Ben-Sira; S Constantini; F Bokstein Journal: AJNR Am J Neuroradiol Date: 2017-08-10 Impact factor: 3.825
Authors: Eva Dombi; Andrea Baldwin; Leigh J Marcus; Michael J Fisher; Brian Weiss; AeRang Kim; Patricia Whitcomb; Staci Martin; Lindsey E Aschbacher-Smith; Tilat A Rizvi; Jianqiang Wu; Rachel Ershler; Pamela Wolters; Janet Therrien; John Glod; Jean B Belasco; Elizabeth Schorry; Alessandra Brofferio; Amy J Starosta; Andrea Gillespie; Austin L Doyle; Nancy Ratner; Brigitte C Widemann Journal: N Engl J Med Date: 2016-12-29 Impact factor: 91.245
Authors: Andrea M Gross; Pamela L Wolters; Eva Dombi; Andrea Baldwin; Patricia Whitcomb; Michael J Fisher; Brian Weiss; AeRang Kim; Miriam Bornhorst; Amish C Shah; Staci Martin; Marie C Roderick; Dominique C Pichard; Amanda Carbonell; Scott M Paul; Janet Therrien; Oxana Kapustina; Kara Heisey; D Wade Clapp; Chi Zhang; Cody J Peer; William D Figg; Malcolm Smith; John Glod; Jaishri O Blakeley; Seth M Steinberg; David J Venzon; L Austin Doyle; Brigitte C Widemann Journal: N Engl J Med Date: 2020-03-18 Impact factor: 91.245
Authors: Vanessa L Merker; Miriam A Bredella; Wenli Cai; Ara Kassarjian; Gordon J Harris; Alona Muzikansky; Rosa Nguyen; Victor F Mautner; Scott R Plotkin Journal: Am J Med Genet A Date: 2014-03-24 Impact factor: 2.802
Authors: Shivani Ahlawat; Laura M Fayad; Muhammad Shayan Khan; Miriam A Bredella; Gordon J Harris; D Gareth Evans; Said Farschtschi; Michael A Jacobs; Avneesh Chhabra; Johannes M Salamon; Ralph Wenzel; Victor F Mautner; Eva Dombi; Wenli Cai; Scott R Plotkin; Jaishri O Blakeley Journal: Neurology Date: 2016-08-16 Impact factor: 9.910
Authors: Rosa Nguyen; Eva Dombi; Brigitte C Widemann; Jeffrey Solomon; Carsten Fuensterer; Lan Kluwe; Jan M Friedman; Victor-Felix Mautner Journal: Orphanet J Rare Dis Date: 2012-10-04 Impact factor: 4.123